131 iodine Report issue

Small molecule Experimental
AACT

Active Ingredient History

NOW
  • Now
Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.   NCATS

Chemistry

  • SMILES: [131I-]
  • InChIKey: XMBWDFGMSWQBCA-RNFDNDRNSA-M
  • Mol. Mass: 130.906124168
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

131 iodine | sun-131

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (2)


 

Hyperthyroidism (approved 1971)

Thyroid Neoplasms (approved 1971)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Chalazion (Phase 3)

Colitis, Ulcerative (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

HIV Infections (Phase 1/Phase 2)

Hyperthyroidism (Phase 3)

Radiofrequency Ablation (Phase 3)

Respiratory Tract Infections (Phase 2)

Thyroid Gland (Phase 3)

Thyroid Neoplasms (Phase 3)

Urinary Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue